Literature DB >> 902452

Effects of probenecid on furosemide kinetics and natriuresis in man.

J Honari, A D Blair, R E Cutler.   

Abstract

Furosemide kinetics were studied in 4 normal subjects after single intravenous injections (1 mg/kg). One experiment was done after pretreatment with probenecid. The apparent volume of furosemide distribution was unchanged after probenecid (10.9 L). The mean plasma clearance fell from 155 to 85 ml/min and the mean plasma t1/2 rose from 36 to 61 min. Renal clearance of furosemide fell below 50% of control after probenecid, but the kidney remained the main route of its excretion (75% of the dose appeared in the urine). In another experiment in 4 subjects an infusion of furosemide was sustained following a loading dose to maintain a constant plasma level. After a control period, probenecid was given orally. This resulted in a decrease in renal excretion of furosemide with a simultaneous rise in its plasma concentration. Despite the rising plasma furosemide concentration, however, there was a diminution in both urine flow and the excreted fraction of filtered sodium, which suggested some reduction of diuretic action. In doses commonly used, probenecid reduces renal elimination of furosemide in man with only a mild impairment of its diuretic activity. This suggests that furosemide is eliminated predominantly by way of proximal tubular secretion and that tubular rather than plasma concentration is the main determinant of its diuretic effect.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 902452     DOI: 10.1002/cpt1977224395

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

1.  Favorable effect on postgraduate clinical practice of a drug-interaction exercise for undergraduate students.

Authors:  Shuichi Tsuruoka; Atsuhiro Kawaguchi; Kazuhiro Harada; Akio Fujimura
Journal:  Eur J Clin Pharmacol       Date:  2006-05-23       Impact factor: 2.953

Review 2.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 3.  Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease.

Authors:  Li Wang; Douglas H Sweet
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

Review 4.  Clinical pharmacokinetics of frusemide.

Authors:  R E Cutler; A D Blair
Journal:  Clin Pharmacokinet       Date:  1979 Jul-Aug       Impact factor: 6.447

Review 5.  Resistance to loop diuretics. Why it happens and what to do about it.

Authors:  D C Brater
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

6.  Effect of probenecid on excretion and natriuretic action of furosemide.

Authors:  F Andreasen; B Sigurd; E Steiness
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

Review 7.  Diuretics. Clinical pharmacology and therapeutic use (Part I).

Authors:  A Lant
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

8.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

9.  Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.

Authors:  M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

10.  The influence of co-administered organic acids on the kinetics and dynamics of frusemide.

Authors:  D K Sommers; E C Meyer; J Moncrieff
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.